Abfero Pharmaceuticals, Inc   Report issue

For profit Phase 2
Founded: Lexington MA United States (2016)
Status: Acquired by Pharmacosmos (2021)

Organization Overview

First Clinical Trial
2019
NCT03801889
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Abfero Pharmaceuticals, Inc

Active Ingredients

Drugs in Phase 2 Trials (1)

sp-420 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

beta-Thalassemia (Phase 2)

Iron Overload (Phase 2)

Thalassemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1